Status:
UNKNOWN
Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection
Lead Sponsor:
Inha University Hospital
Conditions:
Helicobacter Pylori Infection
Compliance, Patient
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
As the antibiotic resistance increases, the eradication rate of triple therapy is decreasing. Recent guideline recommend the use of bismuth-containing quadruple therapy in areas where clarithromycin r...
Detailed Description
In order to be eligible for first-line H. pylori eradication therapy, at least 80% of eradication rate should be achieved by intention to treat (ITT) analysis. However, the triple therapy (PPI, clarit...
Eligibility Criteria
Inclusion
- Participants with peptic ulcer, s/p ESD due to early gastric cancer/gastric adenoma, Maltoma
- Ability and willingness to participate in the study and to sign and give informed consent
- confirmed H. pylori infection
Exclusion
- Previous H. pylori eradication therapy
- Less than 18 years old
- With history of H. pylori infection treatment
- With previous gastric surgery
- Major systemic diseases
- Pregnancy or lactation
- Allergy to any of the study drugs
- Administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion
Key Trial Info
Start Date :
December 30 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 28 2018
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03361267
Start Date
December 30 2017
End Date
June 28 2018
Last Update
December 12 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inha University Hospital
Incheon, South Korea, 22332